A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie
About A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie
During the past decade, A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
2008-02-12
2018-11-23
Completed
808
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
2008-10-16
2029-09-20
Recruiting
720
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
2010-07-31
2016-09-16
Completed
1,095
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
2011-11-08
2028-11-30
Active, not recruiting
4,804
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
2012-05-17
2020-02-19
Completed
2,577
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
2012-09-03
2016-04-30
Terminated
415
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
2013-04-03
2025-04-03
Active, not recruiting
1,487
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
2014-01-31
2021-06-04
Completed
1,846
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie"
#1 collaborator was "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie
According to Clinical.Site data, the most researched conditions in "A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie" are
"Chronic Lymphocytic Leukemia" (1 trials) and "Metastatic Colorectal Cancer" (1 trials). Many other conditions were trialed in "A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie" in a lesser frequency.
Clinical Trials Intervention Types at A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie
Most popular intervention types in "A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie" are "Drug" (2 trials). Other intervention types were less common.
The name of intervention was led by "FOLFIRI + Cetuximab" (1 trials), "Rituximab" (1 trials) and "modifiedFOLFOX6 + Cetuximab" (1 trials). Other intervention names were less common.
Clinical Trials Genders at A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie
The vast majority of trials in "A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie" are
2 trials for "All" genders.
Clinical Trials Status at A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie
Currently, there are NaN active trials in "A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 2 completed trials in A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 1 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".